Electreon Announces Extension of World’s First Wireless Electric Road for Trucks and Buses
11.4.2022 10:00:00 EEST | Business Wire | Press release
Electreon (TASE: ELWS.TA), the leading provider of wireless and in-road wireless electric vehicle (EV) charging technology, today announced the one year extension of the Smartroad Gotland pilot project in Sweden. The €2 million ($2.17 million) budget for the extension is funded by the Swedish Transport Administration and includes an upgrade of 400 m of the existing installation. Electreon will also extend the run of the electric airport shuttle bus—the shuttle will continue to undergo testing and simultaneously be available for commercial rides, and will open to the public in the summer of 2022. Government stakeholders, commercial fleet operators, and businesses interested in the technology are welcome to visit the project site and learn more about the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005166/en/
Electreon has successfully demonstrated the operation of Electric Road Systems at scale utilizing a 40-ton e-truck and a commercial passenger e-bus. (Photo: Business Wire)
“The team at Smartroad Gotland is excited for the one year extension of this project and for the opportunity to demonstrate the continued endurance of our wireless charging technology in Swedish weather,” said Håkan Sundelin, director of the Nordic Region at Electreon and project manager for Smartroad Gotland. “The planned large scale electric road pilot in Sweden, in addition to the French government’s decision to fund pilots for wireless charging roads, shows high demand for Electreon’s technology in Europe.''
Jan Pettersson, program manager of electrification, Swedish Transport Administration said, “We are very positive about the opportunity to test higher wireless charging performance, as well as road durability. Now that the corona restrictions have eased, we are also looking forward to spreading the knowledge from the project more widely.”
As part of the project extension, Electreon will increase the capacity of its receivers to transfer energy to approximately 30 kW and examine a new generation of its technology. This will demonstrate how the wireless charging infrastructure can be upgraded to meet evolving needs over time. Electreon will also deploy its software capabilities, such as its billing feature, which enables the Company to invoice vehicle subscribers using the Electric Road System.
After the upgrade is complete, the long-haul e-truck and commercial passenger e-bus, that have now been utilizing the wireless charging infrastructure for one year as part of this project, will undergo continued testing. The Swedish National Road and Transport Research Institute (VTI) will perform third-party endurance and stress tests to verify that Electreon’s technology and charging coils are unaffected by road construction and heavy-duty truck use. Electreon’s wireless charging technology is designed to be future proof, and this project will continue to prove that Electreon offers long-term performance with minimal maintenance. Additional third-party endurance tests of Electreon’s wireless charging technology are currently being performed as part of the BASt project in Germany and the Arena of the Future project in Italy.
To date, Electreon’s patented technology has been integrated with a wide range of vehicles, as part of its ongoing collaborations with auto manufacturers including Renault, Stellantis, Iveco, and Volkswagen. In February 2022, Electreon announced it was awarded a Michigan Department of Transportation (MDOT) contract for the first public Electric Road System for wireless EV charging in the U.S. In November 2021, Electreon’s wireless charging technology was named one of TIME’s 100 Best Inventions of 2021.
About Electreon
Electreon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. Electreon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005166/en/
Contact information
Media
Janine Ward
On behalf of Electreon
electreon@antennagroup.com
313-536-7806
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom